HAYWARD, Calif., March 1 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, announced today that Phase II clinical trial results for AC-100 (Dentonin(R)) will be presented during an oral presentation in the “Late Breaking News Session” at the Annual Meeting of the American Association for Dental Research (AADR) in Orlando, Fla.
The abstract (#2225), entitled “AC-100, Novel Biological Approach to Promoting Dentin Formation in Humans,” will be presented by Mirella Lazarov, DDS, PhD, director of Pre-Clinical Development at Acologix, on Friday, March 10, at 9:07 a.m. EST in the Walt Disney World Dolphin Hotel, Room Oceanic 1.
“We look forward to presenting these Phase II clinical trial results for AC-100 at the AADR annual meeting, one of the premier dental conferences in the world,” said Yoshi Kumagai, president and CEO of Acologix. “Based on evidence observed to date, we believe that AC-100 represents a novel and promising approach for promoting dentin formation in patients undergoing dental restoration procedures, and could potentially change the way these patients are treated in the future. This is a large and underserved market with more than 200 million dental procedures performed annually in the U.S.”
AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells. It is being developed by Acologix for dental, periodontal and orthopedic applications. AC-100 is currently being studied in two Phase II clinical trials for hard tissue regeneration (i.e., dentin regeneration for dental procedures and oral bone regeneration for periodontal disease).
About Acologix
Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnering with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (or TRK-820) for the treatment of uremic pruritus in dialysis patients. AC-820 is being studied in a European Phase III pivotal clinical trial, with a Phase III trial scheduled to launch in the United States in the second half of 2006. AC-100 (Dentonin(R)), a novel small peptide with dental, periodontal and orthopedic applications, is currently being studied in two Phase II clinical studies, one in dental restoration procedures and another for the repair of periodontal defects. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease. For more information go to www.acologix.com.
Acologix, Inc.
CONTACT: Yoshi Kumagai, President and CEO of Acologix, +1-510-512-7200, oryoshi.kumagai@acologix.com
Web site: http://www.acologix.com/
